D-0646-2020 Class II Terminated

Recalled by AAA Pharmaceutical, Inc. — Lumberton, NJ

FDA drug recall D-0646-2020 was initiated by AAA Pharmaceutical, Inc. on Dec 26, 2019 and is designated Class II. Reason for recall: CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API The recall status is terminated (terminated Mar 10, 2021). Affected quantity: 31,536 (130-count bottles).

Recall details

Product Type
Drugs
Report Date
Jan 15, 2020
Initiation Date
Dec 26, 2019
Termination Date
Mar 10, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
31,536 (130-count bottles)

Product description

Ranitidine 150 mg tablets, 130 count bottles, NDC 37808-196-04.

Reason for recall

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Distribution pattern

Product was distributed to one consignee who may have distributed the product further to their retail stores.

Code information

P134457, Sept 2020 P135156, Aug 2020 P135156, Aug 2020 P135243, Aug 2020 P135877, Sept 2020 P136145, Aug 2020 P136146, Sept 2020 P136623, April 2021 P136728, April, 2021 P136994, April, 2021 P137348, April, 2021 P137423, April, 2021 P137499, April, 2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0646-2020
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for AAA Pharmaceutical, Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0646-2020. Report a data issue: hello@regdatalab.com.